{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:13:58Z","timestamp":1767968038870,"version":"3.49.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R21HD105534"],"award-info":[{"award-number":["R21HD105534"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R43AI170237"],"award-info":[{"award-number":["R43AI170237"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Innovation to streamline the administration of pediatric antiretroviral therapy to infants and small children is urgently needed. The objective of this study was to assess user acceptability of key characteristics of prototype placebo oral dispersible strips (ODS) that would contain a pediatric HIV regimen of abacavir + lamivudine+ dolutegravir (ALD), and the extent to which they would address current barriers to ART adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted 7 focus group discussions with 64 caregivers across three hospitals; 3 FGD with 25 pediatric healthcare providers; and interviews with 25 children living with HIV (6\u201310 years). All FGD and interviews were audio recorded, translated, transcribed verbatim, and coded for a-priori and emergent themes. We evaluated the acceptability of key characteristics of placebo ALD-ODS (e.g.,flavor, size, dose, dissolution time, colors, and packaging) among caregivers, providers, and children using both qualitative and quantitative methods. Data were integrated and triangulated to optimize understanding of stakeholder feedback.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Adult participants preferred the neutral \u201csweet\u201d flavored ALD-ODS which was found highly acceptable among children. Caregivers advocated for a single strip per dose and single dose per day for convenience and to reduce stress of administration. In general, strip size and dissolution time was deemed acceptable, and caregivers stated that a larger size would be acceptable to accommodate a single strip per dose. Providers liked aligning the color of ALD-ODS and its packaging to different weight-based dosing to facilitate dispensing and improve accurate administration among multiple children. Most children stated that they would prefer ALD-ODS to their current regimen given the sweet taste and easy dissolution without the need for water. The competitive advantages of ALD-ODS over traditional pediatric ART options were ease of administration- particularly for infants and small children, a sweet taste, and discretion that protected privacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Providers and caregivers believed the ODS prototypes held great promise to ease ART administration to infants and young children which would improve medication adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0334310","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:35:35Z","timestamp":1761586535000},"page":"e0334310","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["User informed design of oral dispersible strips (ODS) to deliver pediatric antiretroviral therapy in Kenya: A mixed methods evaluation of product preferences and acceptability"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7604-5606","authenticated-orcid":true,"given":"Sarah","family":"Finocchario-Kessler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Maloba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Wexler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Were","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Mugendi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Mbithi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hageman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadrack","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicodemus","family":"Maosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Maliski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Maliski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"pone.0334310.ref001","unstructured":"National Syndemic Diseases Control Council. Kenya AIDS Strategic Framework II: Mid Term Review Report. 2024."},{"key":"pone.0334310.ref002","volume-title":"The urgency of now: AIDS at a crossroads","author":"Joint United Nations Programme on HIV\/AIDS.","year":"2024"},{"issue":"1","key":"pone.0334310.ref003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0296713","article-title":"Challenges with pediatric antiretroviral therapy administration: Qualitative perspectives from caregivers and HIV providers in Kenya","volume":"19","author":"M Sliefert","year":"2024","journal-title":"PLoS One"},{"key":"pone.0334310.ref004","first-page":"1654938","article-title":"The Need for Pediatric Formulations to Treat Children with HIV","volume":"2016","author":"AF Schlatter","year":"2016","journal-title":"AIDS Res Treat"},{"issue":"4","key":"pone.0334310.ref005","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11904-009-0026-8","article-title":"Pediatric adherence to HIV antiretroviral therapy","volume":"6","author":"J Haberer","year":"2009","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"9","key":"pone.0334310.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(22)00101-1","article-title":"Advancing the prevention and treatment of HIV in children: priorities for research and development","volume":"9","author":"M Penazzato","year":"2022","journal-title":"Lancet HIV"},{"issue":"5","key":"pone.0334310.ref007","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1208\/s12248-016-9938-6","article-title":"Defining Patient Centric Pharmaceutical Drug Product Design","volume":"18","author":"S Stegemann","year":"2016","journal-title":"AAPS J"},{"key":"pone.0334310.ref008","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1742-6405-3-30","article-title":"Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals","volume":"3","author":"T Bunupuradah","year":"2006","journal-title":"AIDS Res Ther"},{"issue":"1","key":"pone.0334310.ref009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-008-9168-z","article-title":"Indinavir-loaded pH-sensitive microparticles for taste masking: toward extemporaneous pediatric anti-HIV\/AIDS liquid formulations with improved patient compliance","volume":"10","author":"DA Chiappetta","year":"2009","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"pone.0334310.ref010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0000000000000135","article-title":"The pharmacokinetics and acceptability of lopinavir\/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children","volume":"66","author":"V Musiime","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"pone.0334310.ref011","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3851\/IMP3054","article-title":"Acceptability of lopinavir\/r pellets (minitabs), tablets and syrups in HIV-infected children","volume":"21","author":"A Kekitiinwa","year":"2016","journal-title":"Antivir Ther"},{"key":"pone.0334310.ref012","first-page":"20499361221077544","article-title":"Children living with HIV: a narrative review of recent advances in pediatric HIV research and their implications for clinical practice","volume":"9","author":"D Nalwanga","year":"2022","journal-title":"Ther Adv Infect Dis"},{"issue":"1","key":"pone.0334310.ref013","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2022-001474","article-title":"Optimising neonatal antiretroviral therapy using raltegravir: a qualitative analysis of healthcare workers\u2019 and caregivers\u2019 perspectives","volume":"6","author":"L Katirayi","year":"2022","journal-title":"BMJ Paediatr Open"},{"issue":"4","key":"pone.0334310.ref014","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/jphp.12610","article-title":"Evidence of acceptability of oral paediatric medicines: a review","volume":"69","author":"P Mistry","year":"2017","journal-title":"J Pharm Pharmacol"},{"issue":"10","key":"pone.0334310.ref015","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1111\/bcp.14388","article-title":"Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals","volume":"86","author":"C Timpe","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"pone.0334310.ref016","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jsps.2021.04.025","article-title":"Development of orally dissolving films for pediatric-centric administration of anti-epileptic drug topiramate - A design of experiments (DoE) study","volume":"29","author":"EZ Dahmash","year":"2021","journal-title":"Saudi Pharm J"},{"issue":"2","key":"pone.0334310.ref017","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1208\/s12249-015-0313-1","article-title":"Orally disintegrating films and mini-tablets-innovative dosage forms of choice for pediatric use","volume":"16","author":"M Preis","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"pone.0334310.ref018","volume-title":"Developing Novel Alternative Delivery Strategies for Pediatric HIV Antiretroviral Therapy to Improve Adherence in Kenya","author":"S Finocchario-Kessler","year":"2023"},{"key":"pone.0334310.ref019","volume-title":"Oak Therapeutics","author":"Oak Therapeutics.","year":"2024"},{"key":"pone.0334310.ref020","doi-asserted-by":"crossref","DOI":"10.5888\/pcd15.180128","article-title":"Design Thinking in Health Care","volume":"15","author":"M Altman","year":"2018","journal-title":"Prev Chronic Dis"},{"issue":"3","key":"pone.0334310.ref021","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000002216","article-title":"Human-Centered Design Lessons for Implementation Science: Improving the Implementation of a Patient-Centered Care Intervention","author":"LK Beres","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"pone.0334310.ref022","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000001743","article-title":"A Global Research Agenda for Pediatric HIV","author":"M Penazzato","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"pone.0334310.ref023","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(18)30005-5","article-title":"Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action","volume":"5","author":"M Penazzato","year":"2018","journal-title":"Lancet HIV"},{"key":"pone.0334310.ref024","volume-title":"Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01).","author":"National Institutes of Health","year":"2018"},{"issue":"1","key":"pone.0334310.ref025","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1186\/s12913-023-10078-6","article-title":"Assessing user preferences for design characteristics of oral dissolvable strips for pediatric HIV medication: a qualitative study","volume":"23","author":"C Wexler","year":"2023","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"pone.0334310.ref026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1108\/IJPL-08-2020-0072","article-title":"An analysis of groupthink and decision making in a collectivism culture: the case of a public organization in Tanzania","volume":"18","author":"CG Tarmo","year":"2021","journal-title":"IJPL"},{"issue":"7","key":"pone.0334310.ref027","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25717","article-title":"Early ART initiation during infancy preserves natural killer cells in young European adolescents living with HIV (CARMA cohort)","volume":"24","author":"M Doria","year":"2021","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"pone.0334310.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281528","article-title":"HIV virologic response, patterns of drug resistance mutations and correlates among adolescents and young adults: A cross-sectional study in Tanzania","volume":"18","author":"J Rugemalila","year":"2023","journal-title":"PLoS One"},{"issue":"7","key":"pone.0334310.ref029","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/hiv.13635","article-title":"Availability and stock-outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda","volume":"25","author":"TG Jacobs","year":"2024","journal-title":"HIV Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:35:41Z","timestamp":1761586541000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334310"}},"subtitle":[],"editor":[{"given":"Amjad","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0334310","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}